Biondvax Pharmaceuticals Stock Current Asset
| BVXVDelisted Stock | USD 1.35 0.03 2.17% |
BiondVax Pharmaceuticals fundamentals help investors to digest information that contributes to BiondVax Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of BiondVax Stock. The fundamental analysis module provides a way to measure BiondVax Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to BiondVax Pharmaceuticals stock.
BiondVax |
BiondVax Pharmaceuticals Company Current Asset Analysis
BiondVax Pharmaceuticals' Current Asset is all of the company's assets that can be used to pay off current liabilities within the current fiscal period or over the next 12 months. Current Asset includes cash or cash equivalents, accounts receivable, short-term investments, and the portion of prepaid liabilities which will be paid within the next 12 months. Because these assets are easily turned into cash, they are sometimes referred to as liquid assets.
Current BiondVax Pharmaceuticals Current Asset | 36.93 M |
Most of BiondVax Pharmaceuticals' fundamental indicators, such as Current Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, BiondVax Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Current Asset is important to company's creditors and private equity firms as they will often be interested in how much that company has in current assets since these assets can be easily liquidated in case the company goes bankrupt. However, it is usually not enough to know if a company is in good shape just based on current asset alone; the amount of current liabilities should always be considered.
CompetitionIn accordance with the recently published financial statements, BiondVax Pharmaceuticals has a Current Asset of 36.93 M. This is 98.28% lower than that of the Pharmaceuticals sector and 96.52% lower than that of the Health Care industry. The current asset for all United States stocks is 99.6% higher than that of the company.
BiondVax Current Asset Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses BiondVax Pharmaceuticals' direct or indirect competition against its Current Asset to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of BiondVax Pharmaceuticals could also be used in its relative valuation, which is a method of valuing BiondVax Pharmaceuticals by comparing valuation metrics of similar companies.BiondVax Pharmaceuticals is currently under evaluation in current asset category among its peers.
BiondVax Fundamentals
| Return On Equity | -56.02 | |||
| Return On Asset | -0.31 | |||
| Current Valuation | 21.94 M | |||
| Shares Outstanding | 3.65 M | |||
| Shares Owned By Insiders | 20.01 % | |||
| Shares Owned By Institutions | 10.69 % | |||
| Number Of Shares Shorted | 4.88 K | |||
| Price To Earning | (4.91) X | |||
| Price To Book | 7.48 X | |||
| EBITDA | (10.5 M) | |||
| Net Income | (5.8 M) | |||
| Cash And Equivalents | 14.55 M | |||
| Cash Per Share | 2.23 X | |||
| Total Debt | 21.54 M | |||
| Current Ratio | 1.71 X | |||
| Book Value Per Share | (1.96) X | |||
| Cash Flow From Operations | (7.26 M) | |||
| Short Ratio | 0.32 X | |||
| Earnings Per Share | (2.35) X | |||
| Target Price | 39.0 | |||
| Number Of Employees | 33 | |||
| Beta | 2.37 | |||
| Market Capitalization | 4.97 M | |||
| Total Asset | 27.07 M | |||
| Retained Earnings | (115.83 M) | |||
| Working Capital | 12.03 M | |||
| Current Asset | 36.93 M | |||
| Current Liabilities | 1.7 M | |||
| Z Score | -6.6 | |||
| Net Asset | 27.07 M |
About BiondVax Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze BiondVax Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of BiondVax Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of BiondVax Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in interest. You can also try the Price Ceiling Movement module to calculate and plot Price Ceiling Movement for different equity instruments.
Other Consideration for investing in BiondVax Stock
If you are still planning to invest in BiondVax Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the BiondVax Pharmaceuticals' history and understand the potential risks before investing.
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance |